$AZN
Market Cap:
$AZN SEC Filings
| Filing | Filed On |
|---|---|
| TOTAL VOTING RIGHTS | 04 Sep 2018 |
| ASTRAZENECA UPDATE ON ANIFROLUMAB IN SLE | 31 Aug 2018 |
| EC APPROVES BYDUREON BCISE DEVICE FOR T2 DIABETES | 30 Aug 2018 |
| ASTRAZENECA PIIIB TRIAL UPDATE FOR BEVESPI IN COPDASTRAZENECA PIIIB TRIAL UPDATE | 23 Aug 2018 |
| AZ'S TAGRISSO APPROVED IN JAPAN FOR 1ST-LINE NSCLC | 21 Aug 2018 |
| FORM 6-K | 17 Aug 2018 |
| ASTRAZENECA PRICES A $3BN BOND ISSUE | 15 Aug 2018 |
| 6-K | 10 Aug 2018 |
| EMA GRANTS OD FOR SELUMETINIB IN NF1 | 03 Aug 2018 |
| TOTAL VOTING RIGHTS | 01 Aug 2018 |
| CHMP RECOMMENDS IMFINZI FOR STAGE III NSCLC | 27 Jul 2018 |
| 6-K | 26 Jul 2018 |
| ATACAND TO BE DIVESTED TO CHEPLAPHARM IN EUROPE | 24 Jul 2018 |
| HOLDING(S) IN COMPANY | 18 Jul 2018 |
| TOTAL VOTING RIGHTS | 02 Jul 2018 |
| LYNPARZA APPROVED IN JAPAN FOR BRCAM BREAST CANCER | 02 Jul 2018 |
| IMFINZI APPROVED IN JAPAN FOR STAGE III NSCLC | 02 Jul 2018 |
| BYDUREON RECEIVES POSITIVE CHMP OPINION FOR BCISE | 29 Jun 2018 |
| AZ AND LUYE PHARMA COMPLETE AGREEMENT FOR SEROQUEL | 28 Jun 2018 |
| LYNPARZA: SIGNIFICANT PFS 1ST-LINE OVARIAN CANCER | 27 Jun 2018 |
